HUP0101689A3 - Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease - Google Patents

Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease

Info

Publication number
HUP0101689A3
HUP0101689A3 HU0101689A HUP0101689A HUP0101689A3 HU P0101689 A3 HUP0101689 A3 HU P0101689A3 HU 0101689 A HU0101689 A HU 0101689A HU P0101689 A HUP0101689 A HU P0101689A HU P0101689 A3 HUP0101689 A3 HU P0101689A3
Authority
HU
Hungary
Prior art keywords
lupus
reversal
antibodies
treatment
kidney disease
Prior art date
Application number
HU0101689A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Trustees Of Darmouth College H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trustees Of Darmouth College H filed Critical Trustees Of Darmouth College H
Publication of HUP0101689A2 publication Critical patent/HUP0101689A2/hu
Publication of HUP0101689A3 publication Critical patent/HUP0101689A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HU0101689A 1998-04-03 1999-04-02 Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease HUP0101689A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5448898A 1998-04-03 1998-04-03
PCT/US1999/007321 WO1999051258A1 (en) 1998-04-03 1999-04-02 USE OF ANTI-gp39 ANTIBODIES FOR TREATMENT AND/OR REVERSAL OF LUPUS AND ASSOCIATED KIDNEY DISEASE

Publications (2)

Publication Number Publication Date
HUP0101689A2 HUP0101689A2 (hu) 2001-08-28
HUP0101689A3 true HUP0101689A3 (en) 2004-08-30

Family

ID=21991433

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101689A HUP0101689A3 (en) 1998-04-03 1999-04-02 Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease

Country Status (9)

Country Link
EP (1) EP1067954A4 (OSRAM)
JP (1) JP2002510643A (OSRAM)
KR (1) KR20010072564A (OSRAM)
CN (2) CN100352497C (OSRAM)
AU (1) AU743824B2 (OSRAM)
HU (1) HUP0101689A3 (OSRAM)
NO (1) NO20004966L (OSRAM)
TW (1) TWI224969B (OSRAM)
WO (1) WO1999051258A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
EA201890434A1 (ru) 2015-08-05 2018-10-31 Янссен Байотек, Инк. Антитела к cd154 и способы их применения
SG10202111207TA (en) 2017-05-24 2021-11-29 Als Therapy Development Inst Therapeutic anti-cd40 ligand antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
NZ337072A (en) * 1997-01-10 2000-12-22 Biogen Inc use of an anti-CD40L compounds to inhibit the progression of nephritis, stabilize nephritis or reverse nephritis in a patient with an immune complex disease
AU5623398A (en) * 1997-03-07 1998-09-22 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds
WO1999000143A1 (en) * 1997-06-27 1999-01-07 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases

Also Published As

Publication number Publication date
CN1173735C (zh) 2004-11-03
NO20004966L (no) 2000-12-04
AU3379699A (en) 1999-10-25
EP1067954A1 (en) 2001-01-17
EP1067954A4 (en) 2004-08-18
CN100352497C (zh) 2007-12-05
TWI224969B (en) 2004-12-11
NO20004966D0 (no) 2000-10-02
JP2002510643A (ja) 2002-04-09
CN1757413A (zh) 2006-04-12
KR20010072564A (ko) 2001-07-31
HUP0101689A2 (hu) 2001-08-28
WO1999051258A1 (en) 1999-10-14
AU743824B2 (en) 2002-02-07
CN1303301A (zh) 2001-07-11

Similar Documents

Publication Publication Date Title
PT1083889E (pt) Compostos de tetra-hidronaftaleno e sua utilizacao no tratamento de doencas neurodegenerativas
DE69805438D1 (de) Misch- und ladeöffnung zur medizinischen behandlung
EP1071458A4 (en) HUMANIZED ANTIBODIES AND CORRESPONDING USES THEREOF
AU7165698A (en) Use of quinazoline compounds for the treatment of polycystic kidney disease
IL214084A0 (en) TREATMENT WITH ANTI ErbB2 ANTIBODIES
PH31420A (en) Methods of use for inhibiting bone loss and lowering serum cholesteol.
PT1818343E (pt) Anticorpos contra a il-12 humana
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
AU4799499A (en) Human proteins having hydrophobic domains and dnas encoding these proteins
DE69926685D1 (de) Toner und Bildherstellungsverfahren
DE69921552D1 (de) Toner und Bildherstellungsverfahren
DE69725794D1 (de) Granulat zur Abwasserbehandlung
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
AU1181900A (en) Human proteins having hydrophobic domains and dnas encoding these proteins
IL133136A0 (en) Use of leptin antagonists for the treatment of diabetes
AU6321400A (en) Human proteins having hydrophobic domains and dnas encoding these proteins
AU5249800A (en) Human proteins having hydrophobic domains and dnas encoding these proteins
AU3760400A (en) Methods and reagents for the diagnosis and treatment of multiple sclerosis
AU4196697A (en) Use of igf-i for the treatment of polycystic kidney disease and related indications
HUP9700676A3 (en) Anti-fas recombinante antibodies and dna coding thereof
AU4167499A (en) Human proteins having hydrophobic domains and dnas encoding these proteins
AU5249700A (en) Human proteins having hydrophobic domains and dnas encoding these proteins
EP1140121A4 (en) CRYOGRANULATION OF ACTIVATED PROTEIN C
EP1107778A4 (en) TREATMENT OF DISEASE CONDITIONS
AU1487597A (en) Treatment of septic shock with anti-TNF antibodies

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees